CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/ This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate m…

CME credits: 0.25 Valid until: 26-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/ Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with…

CME credits: 0.50 Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-major-depressive-disorder-with-insomnia/36556/ Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Jo…

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-tipping-the-balance/39660/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervent…

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/diagnosing-minimal-hepatic-encephalopathy-theres-an-app-for-that/39662/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely d…

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/treatment-of-overt-hepatic-encephalopathy/39664/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and interventi…

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-unmet-therapeutic-needs/39665/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and inter…

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/you-cant-diagnose-mhe-unless-you-diagnose-cirrhosis/39661/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and …

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/the-clinical-spectrum-of-hepatic-encephalopathy/39304/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and inte…

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-whats-sarcopenia-got-to-do-with-it/39663/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosi…

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-an-ominous-sign/39666/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention.…

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-an-ominous-sign/39278/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention.…

CME credits: 1.00 Valid until: 22-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/endovoice-live-endometriosisa-chronic-burden-of-reproductive-years/37176/ This dynamic symposium will guide clinicians through a modern, patient-centered approach to endometriosis care. Faculty will explore how early diagnosis can improve physical an…

CME credits: 1.00 Valid until: 22-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-shining-light-on-an-invisible-female-health-burden/36709/ This WHAV 2025 session examines primary biliary cholangitis (PBC), a chronic autoimmune liver disease that predominantly affects women and often goes unrecognized. …

CME credits: 0.50 Valid until: 21-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-ohcm-the-emerging-role-of-cardiac-myosin-inhibitors/33176/ Hypertrophic cardiomyopathy (HCM) management is being transformed by advances in diagnostics and the emergence of targeted therapies. In this program, lea…

CME credits: 1.00 Valid until: 20-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-and-treating-ibs-it-begins-with-one-simple-question/36607/ Presented at the 21st Annual Women’s Health Annual Visit (WHAV 2025), this session reviews strategies for diagnosing and treating irritable bowel syndrome (IBS), with a focus on di…

CME credits: 1.00 Valid until: 15-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/womens-sleep-health-addressing-gaps-in-osa-diagnosis-and-treatment-across-life-stages/36099/ This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discus…

CME credits: 0.50 Valid until: 30-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-in-anti-pd-1-strategies-for-her2-negative-upper-gi-cancers/37690/ This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testin…

CME credits: 0.50 Valid until: 30-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/quick-case-strategizing-treatment-selection-in-her2-pd-l1-gastric-cancer/37692/ This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testi…

CME credits: 0.50 Valid until: 30-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/distinguishing-first-line-treatment-adverse-event-profiles-in-her2-negative-upper-gi-cancers/37691/ This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the rol…

CME credits: 0.50 Valid until: 30-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-in-first-line-treatment-of-her2-negative-upper-gi-cancers/37689/ This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biom…

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-esmo-2025/39978/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC).…

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/rethinking-the-therapeutic-targeting-of-b7-h3-in-es-sclc/37876/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts wi…

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-implications-of-emerging-data-on-b7-h3directed-adcs-in-the-future-of-es-sclc/39979/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer …

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-criteria-and-imaging-strategies-for-b7-h3directed-adcs-in-es-sclc/39977/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). …

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/translating-clinical-data-into-multidisciplinary-practice-for-es-sclc/37878/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Facul…

CME credits: 1.00 Valid until: 26-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-resistance-to-response-evolving-strategies-in-mdd-management/32847/ Can you recognize the symptoms of major depressive disorder? Do you know when to augment and when to switch therapies? Join our experts for these answers and learn about novel t…

CME credits: 0.50 Valid until: 11-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-wclc-2025/37877/ This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC).…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/bronchiectasis-update-diagnostic-innovations-and-therapeutic-frontiers/37233/ Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammat…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/deara-versus-soc-in-fsgs-management-clinical-trial-insights/37188/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/fsgs-when-solutions-fall-short/37183/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/current-fsgs-treatment-landscape-more-questions-than-answers/37184/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatmen…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-the-patient-voice-in-fsgs-management/37190/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standa…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/fsgs-interpretation-of-proteinuria-reduction-thresholds/37185/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-considerations-for-pediatric-patients-with-fsgs/37189/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment a…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/future-directions-in-fsgs-care/37191/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy…

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-managing-adult-and-pediatric-patients-with-fsgs-latest-data/37186/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current …

CME credits: 1.00 Valid until: 19-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/monitoring-fsgs-traditional-and-novel-biomarkers/37187/ Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standa…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Real-World-Evidence-of-Photobiomodulation-Efficacy-in-Ocular-Indications/35952/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Patient-Centered-Care-and-Integration-of-Photobiomodulation-Therapy-into-Clinical-Practice/35950/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degene…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Integration-of-Photobiomodulation-Therapy-into-the-Age-Related-Macular-Degeneration-Treatment-Landscape/35951/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related m…

CME credits: 1.00 Valid until: 16-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/Photobiomodulation-A-Non-Invasive-Treatment-for-Ocular-Disease-and-Trauma/35945/ This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hea…